{"id":21085,"date":"2023-08-10T20:30:00","date_gmt":"2023-08-10T20:30:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4181078_AE81078_0"},"modified":"2023-08-10T20:30:00","modified_gmt":"2023-08-10T20:30:00","slug":"ys-biopharma-to-report-first-quarter-fiscal-year-2024-financial-results-on-august-15-2023","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=21085","title":{"rendered":"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023"},"content":{"rendered":"
\n\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

GAITHERSBURG, Md.<\/span><\/span>, Aug. 10, 2023<\/span><\/span> \/PRNewswire\/ — YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first quarter ended June 30, 2023, after the U.S. market closes on Tuesday, August 15, 2023.<\/p>\n

The Company’s management will hold an earnings conference call at 8:00 P.M. Eastern Time on Tuesday, August 15, 2023<\/span> to discuss the financial results. Listeners may access the call by dialing the following numbers:<\/p>\n

\n\n\n\n\n\n\n\n
\n

United States Toll Free:                 1-888-346-8982<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

International:                                  1-412-902-4272<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Mainland China Toll Free:              4001-201203<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Canada Toll Free:                          1-855-669-9657<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Hong Kong:                                    852-301-84992<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

Upon dialing-in, participants should ask to be joined into the YS Biopharma Co., Ltd. call.<\/p>\n

The replay will be accessible through August 22, 2023 by dialing the following numbers:<\/p>\n

\n\n\n\n\n\n\n
\n

United States Toll Free:                 1-877-344-7529<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

International:                                  1-412-317-0088<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Canada Toll Free:                           855-669-9658<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Access Code:                                 8167733<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https:\/\/investor.ysbiopharm.com\/<\/a>.<\/p>\n

About YS Biopharma<\/b><\/p>\n

YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA\u00ae<\/sup> immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates in China, the United States, Singapore, and the Philippines<\/span>, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharm.com<\/a>.<\/p>\n

Investor Relations Contact
<\/b>Robin Yang<\/span>
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com<\/a><\/p>\n

Alyssa Li<\/span>
Director of Investor Relations
Email: ir@yishengbio.com<\/a> <\/p>\n<\/p><\/div>\n

Source: YS Biopharma Co., Ltd.<\/p>\n","protected":false},"excerpt":{"rendered":"

GAITHERSBURG, Md., Aug. 10, 2023 \/PRNewswire\/ — YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first quarter ended June […]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-21085","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"\nYS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=21085\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 - My Blog\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Aug. 10, 2023 \/PRNewswire\/ — YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first quarter ended June […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=21085\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-10T20:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023\",\"datePublished\":\"2023-08-10T20:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085\"},\"wordCount\":483,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1911441\\\/YS_Biopharma_Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085\",\"name\":\"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1911441\\\/YS_Biopharma_Logo.jpg?p=medium600\",\"datePublished\":\"2023-08-10T20:30:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1911441\\\/YS_Biopharma_Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1911441\\\/YS_Biopharma_Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21085#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=21085","og_locale":"en_US","og_type":"article","og_title":"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 - My Blog","og_description":"GAITHERSBURG, Md., Aug. 10, 2023 \/PRNewswire\/ — YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first quarter ended June […]","og_url":"https:\/\/transmediavictoria.net.au\/?p=21085","og_site_name":"My Blog","article_published_time":"2023-08-10T20:30:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=21085#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=21085"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023","datePublished":"2023-08-10T20:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=21085"},"wordCount":483,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=21085#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=21085","url":"https:\/\/transmediavictoria.net.au\/?p=21085","name":"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=21085#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=21085#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600","datePublished":"2023-08-10T20:30:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=21085#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=21085"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=21085#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=21085#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/21085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21085"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/21085\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}